Conference Proceedings

First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study

Michael L Wang, Wojciech Jurczak, Karl Eckert, Jennifer Lin, Jutta Neuenburg, Constantine Tam

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | CIG MEDIA GROUP, LP | Published : 2020